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Aims Inhibition of sodium–glucose co-transporter 2 (SGLT2) reduces the risk of death and heart failure (HF) admissions
in patients with chronic HF. However, safety and clinical efficacy of SGLT2 inhibitors in patients with acute
decompensated HF are unknown.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
In this randomized, placebo-controlled, double-blind, parallel group, multicentre pilot study, we randomized 80
acute HF patients with and without diabetes to either empagliflozin 10 mg/day or placebo for 30 days. The primary
outcomes were change in visual analogue scale (VAS) dyspnoea score, diuretic response (weight change per 40 mg
furosemide), change in N-terminal pro brain natriuretic peptide (NT-proBNP), and length of stay. Secondary
outcomes included safety and clinical endpoints. Mean age was 76 years, 33% were female, 47% had de novo HF and
median NT-proBNP was 5236 pg/mL. No difference was observed in VAS dyspnoea score, diuretic response, length
of stay, or change in NT-proBNP between empagliflozin and placebo. Empagliflozin reduced a combined endpoint of
in-hospital worsening HF, rehospitalization for HF or death at 60 days compared with placebo [4 (10%) vs. 13 (33%);
P = 0.014]. Urinary output up until day 4 was significantly greater with empagliflozin vs. placebo [difference 3449
(95% confidence interval 578–6321) mL; P< 0.01]. Empagliflozin was safe, well tolerated, and had no adverse effects
on blood pressure or renal function.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusions In patients with acute HF, treatment with empagliflozin had no effect on change in VAS dyspnoea, diuretic response,
NT-proBNP, and length of hospital stay, but was safe, increased urinary output and reduced a combined endpoint of
worsening HF, rehospitalization for HF or death at 60 days.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Acute heart failure • Empagliflozin • Sodium–glucose co-transporter 2 • Hospital readmission •
Dyspnoea • Diuresis • Renal function • Blood pressure
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Introduction
Multiple randomized clinical trials indicated that sodium–glucose
co-transporter 2 (SGLT2) inhibitors reduce the risk for heart
failure (HF) hospitalization in patients with type 2 diabetes.1–4
Although only a minority of patients included in these trials had
pre-existing HF, the results showed the potential to also improve
outcomes in patients with established HF.3,5–8 Beneficial effects
in patients with established chronic HF were shown in a recent
trial where the SGLT2 inhibitor dapagliflozin reduced the risk of
death and HF admissions in patients with established chronic HF
with a reduced ejection fraction (HFrEF), either with or without
diabetes.9 These beneficial effects are at least partly explained by
the diuretic/natriuretic effects of SGLT2 inhibitors, although other
mechanisms such as direct cardiometabolic and renal enhancing
effects have been proposed as well.10–12
Acute (decompensated) HF is one of the leading causes of
hospital admissions worldwide with a post-discharge mortality
and rehospitalization risk as high as 20–30% within the first 3
to 6 months. Unlike chronic HF, there is no established therapy
available that improves clinical outcome in acute HF.13 Despite
treatment with loop diuretics, many are discharged with resid-
ual congestion, which is related to an even higher risk of early
rehospitalization and death.14 Renal failure and worsening renal
function in patients with acute HF are common and related to an
impaired outcome when diuretic response is poor.15,16 Based on
both the promising pharmacological profile of the SGLT2 inhibitor
empagliflozin and the demonstrated benefits on HF and renal out-
comes, we hypothesized that empagliflozin exerts positive effects




EMPA-RESPONSE-AHF was an investigator initiated randomized,
placebo-controlled, double-blind, parallel group, multicentre pilot
study in subjects admitted for acute (decompensated) HF. Patients
with and without type 2 diabetes mellitus could participate. A total of
80 eligible subjects were randomized in a 1:1 ratio to receive either
empagliflozin 10 mg/day or matched placebo. A blocked randomiza-
tion was used (size 4), with stratification by study site. Investigators
used a web-based randomization system to determine treatment
assignment. The trial was executed in five cardiology centres in
the Netherlands (online supplementary Appendix S1). The trial was
approved by the ethics committee at each study centre and the study
was conducted in accordance with the Declaration of Helsinki and
the International Conference on Harmonisation Guidelines for Good
Clinical Practice. All participating patients provided written informed
consent. This trial was registered with ClinicalTrials.gov, number
NCT03200860.
Patient population
Eligible patients were male or female aged >18 years who were hos-
pitalized for acute HF, defined as all of the following: (i) dyspnoea at



















































































.. rales, and/or congestion on chest radiograph, (iii) brain natriuretic
peptide (BNP) ≥350 pg/mL or N-terminal pro BNP (NT-proBNP)
≥1400 pg/mL (for patients with atrial fibrillation: BNP ≥500 pg/mL
or NT-proBNP ≥2000 pg/mL), and (iv) treated with loop diuretics at
screening. Patients needed to have an estimated glomerular filtration
rate (based on the Chronic Kidney Disease Epidemiology Collabora-
tion formula17) ≥ 30 mL/min/1.73 m2 between presentation and ran-
domization. Exclusion criteria were: (i) type 1 diabetes mellitus, (ii)
dyspnoea primarily due to non-cardiac causes, (iii) cardiogenic shock,
(iv) acute coronary syndrome within 30 days prior to randomization,
(v) planned or recent percutaneous or surgical coronary interven-
tion within 30 days prior to randomization, (vi) signs of ketoacidosis
and/or hyperosmolar hyperglycaemic syndrome (pH> 7.30 and glucose
>15 mmol/L and HCO3 > 18 mmol/L), (vii) pregnant or nursing (lactat-
ing) women, (viii) current participation in any interventional study, (ix)
inability to follow instructions or comply with follow-up procedures,
(x) any other medical conditions that would put the patient at risk or
influence study results in the investigator’s opinion, or that the investi-
gator deemed unsuitable for the study.
Patients were randomized within 24 h of presentation to the
hospital. After informed consent, patients were randomly assigned
to one of the treatment groups and received the assigned (blinded)
therapy after baseline assessment, which included assessment of HF
signs and symptoms, visual analogue scale (VAS) dyspnoea score,
vital signs, demographics, and urine and plasma sampling. During
4 days following randomization, patients were evaluated daily per
protocol and included evaluation of HF signs and symptoms, vital
signs, weight, laboratory assessments (including NT-proBNP at day
4), plasma and urine sampling and assessment of adverse events
(AE). Three of four primary outcome measures (VAS dyspnoea
score, NT-proBNP, diuretic response) were assessed at day 4. If a
patient was discharged before day 4, assessment took place out-
side the hospital at day 4. Randomized treatment was continued
through day 30, when a study visit was carried out and assessments
were repeated. Patients were followed until day 60 for AE, and the
study was concluded by a telephone call at day 60 to assess AE and
vital status.
Study endpoints
The primary endpoints of this study were (i) change in dyspnoea
VAS from baseline to day 4, (ii) diuretic response (defined as Δ
weight kg/[(total intravenous dose)/40 mg]+ [(total oral dose)/80 mg)]
furosemide or equivalent loop diuretic dose) through day 4,18 (iii)
length of initial hospital stay, and (iv) percentage change in NT-proBNP
from baseline to day 4.
Secondary endpoints of the study included worsening HF (defined as
worsening signs and/or symptoms of HF that require an intensification
of intravenous therapy for HF or mechanical ventilatory, renal or
circulatory support), all-cause death and/or HF readmission through
day 30 and through day 60 as part of AE assessment.
Safety endpoints included (i) AE (general), (ii) AE that lead to
treatment discontinuation, (iii) serious AE (which could include a
secondary endpoint), (iv) AE of special interest (AESI), including hepatic
injury, worsening renal function, metabolic acidosis, ketoacidosis and
diabetic ketoacidosis (online supplementary Methods S1).
Randomized treatment was required to be discontinued per proto-
col if systolic blood pressure dropped below 90 mmHg or decreased
below 100 mmHg with signs/symptoms of hypotension, or signs
of ketoacidosis and/or hyperosmolar hyperglycaemic syndrome, or
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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any increase in serum creatinine >50%. Treating physicians were
encouraged to reinitiate randomized treatment after resolution of the
above mentioned criteria.
Statistical analysis
Normally distributed continuous variables are presented as
mean± standard deviation (SD), non-normally distributed vari-
ables as median and 25th–75th percentile. Categorical variables are
presented as numbers (percentage).
Power calculation was based on capturing the primary outcome
measures in the placebo group with a degree of certainty. With 40
patients in the control group, a given mean continuous response can
be estimated within ±0.2 SD with 80% confidence intervals (CI). We
estimated the following mean responses for the primary outcome
measures (in the placebo group):
1 Change in VAS dyspnoea score: 1756± 2353 mm× h at day 4.
2 Diuretic response [of 0.56± 0.78 kg/40 mg furosemide (or equiva-
lent)] at day 4.
3 Length of stay 9.6 to 10.5 days (± 9.1).
4 Percentage change in NT-proBNP 24 (−1.0–88.7)% (SD 67%) at
day 4.
Consequently, 40 patients per group would provide approximately
80% power to detect standardized mean treatment differences of
approximately 0.48 SDs at the two-sided 20% significance level for this
pilot study. The difference in change in dyspnoea VAS from baseline to
day 4 was assessed by comparing the area under the curve (AUC) of
change in VAS dyspnoea score by Student’s t-test. To do so, individual
changes in VAS score were visualized (virtually) as a curve where the
x-axis shows study day baseline to day 4, and y-axis shows VAS score.
Using this approach, AUC for each study day (trapezoids) can be
calculated, and added together, resulting in an overall VAS AUC score
(mm× h) that can be compared across treatment groups.19 Difference
in diuretic response and percentage change in NT-proBNP at day
4 was assessed by Student’s t-test. Difference in length of stay was
assessed by Wilcoxon rank-sum test. All analyses were carried out in
the full analysis set based on the intention-to-treat principle where all
randomized patients were analysed. As this was an exploratory study
with limited power, all four individual primary endpoints were tested
separately, with no formal correction for multiplicity. Only as a sen-
sitivity analysis, if at least two out of four primary endpoints showed
significant difference in the same direction (favouring either investi-
gational drug or placebo), a Bonferroni correction would be applied
(P< 0.05).
As an exploratory analysis, and for graphical presentation, individual
responses to the above-mentioned endpoints were standardized. This
was done by dividing the difference from the overall mean (or log
transformed mean if non-normally distributed) of each endpoint by the
overall SD of that variable, which generates a z-score. The treatment
effect can then be measured by the mean difference of standardized
z-scores, which was visually presented on a forest plot by mean ± 80%
CI (given P< 0.2).
Then, all four standardized scores for each individual endpoints
were averaged, and mean treatment difference and associated 95% CI
for this overall treatment effect visually presented. Statistical analysis
for the treatment difference was carried out by Student’s t-test. Two
tailed P-values <0.2 were considered statistically significant for the























































































From December 2017 through July 2019 patients were enrolled
at five centres in the Netherlands. The CONSORT diagram
of this study is presented in Figure 1. A total of 80 patients
were randomized (41 to empagliflozin and 39 to placebo). One
patient randomized to empagliflozin withdrew informed con-
sent, leaving 40 empagliflozin and 39 placebo patients for our
analyses. Table 1 shows the baseline characteristics in the two
groups. Mean age of the patients was 76 years, 33% were female,
47% had de novo acute HF, mean left ventricular ejection frac-
tion was 36%, and median NT-proBNP was 5236 pg/mL. One
third of patients had type 2 diabetes mellitus. Groups were
reasonably well-balanced, although patients in the empagliflozin
group were older, more often female and had lower NT-proBNP
levels.
Primary outcome
Results of the primary endpoints are presented in Figure 2.
The AUC of the change in dyspnoea VAS over the first
4 days was 1264± 1211 mm× h) in the empagliflozin group
vs. 1650± 1240 mm× h in the placebo group (P = 0.18). Diuretic
response through day 4 was −0.35± 0.44) kg/40 mg furosemide
equivalents in the empagliflozin group vs. −0.12±1.52 kg/40 mg
furosemide equivalents in the placebo group (P = 0.37). Percent-
age change in NT-proBNP through day 4 was −46± 32% in the
empagliflozin group vs. −42± 31% in the placebo group (P = 0.63).
Length of hospital stay was 8 (6–10) days in the empagliflozin
group vs. 8 (6–9) days in the placebo group (P = 0.58). There were
no differences in the primary outcome measures in subgroups of
de novo vs. decompensated HF.
A summary of the four endpoints, standardized by z-scores,
are presented in Figure 3. The overall combined z-score was not
significantly different between empagliflozin and placebo (mean
difference−0.019, 95% CI −0.306 to 0.269; P = 0.90).
Secondary and exploratory analyses
Figure 4 shows the incidence of in-hospital worsening HF,
death, and/or HF hospital readmission. A combined endpoint
of in-hospital worsening HF, rehospitalization for HF or all-cause
death at 60 days occurred in 4 patients (10%) in the empagliflozin
group vs. 13 patients (33%) in the placebo group (P = 0.014).
Online supplementary Table S1 provides the data for the individual
components. There was a greater, but not statistically different,
drop in diastolic blood pressure in the empagliflozin treated
patients, similar reductions in systolic blood pressure and heart
rate, and no differences in renal function were demonstrated up
until day 4 (online supplementary Figure S1). Patients randomized
to empagliflozin more often had a diuretic response better than
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
716 K. Damman et al.
Figure 1 CONSORT diagram. ACS, acute coronary syndrome; AHF, acute heart failure; eGFR, estimated glomerular filtration rate; HHS,
hyperosmolar hyperglycaemic syndrome; NP, natriuretic peptide; NT-proBNP, N-terminal pro brain natriuretic peptide; VAS, visual analogue
scale.
0.4 kg decrease/40 mg furosemide equivalent compared with
placebo (42% vs. 24%, P = 0.14).
In a subset of patients, urinary output and net fluid loss were
available. The effects of empagliflozin on urinary output and net
fluid balance are presented in Figure 5. At day 1, there was a signif-
icantly greater urine output with empagliflozin (3442± 1922 mL)
compared with placebo (2400± 993 mL) (P = 0.013; n = 58).
Net fluid loss at day 1 was also greater with empagliflozin
(−2163± 1896 mL) compared with placebo (−1007± 1049 mL)
(P = 0.009; n = 53). After 4 days, the difference in cumulative
urine output (3449, 95% CI 578–6321 mL; n = 28) was signifi-
cantly greater (P = 0.02), whereas net fluid loss with empagliflozin
was greater (2701, 95% CI −586 to 8988 mL, n = 25; P = 0.10).
Weight change after 4 days was −2.83± 3.15 kg in the empagliflozin
group vs. −2.30± 3.26 kg in the placebo group (P = 0.48). Median
loop diuretic dose (re-calculated to furosemide) through day 4
was 320 (194–466) mg furosemide in the empagliflozin group and



























Safety data are presented in Table 2. The incidence rates of AE were
similar in subjects treated with placebo or empagliflozin. Patients
randomized to empagliflozin had significantly lower number of car-
diovascular AE compared with placebo (9 vs. 17 events, P = 0.046).
This was mostly due to more frequent worsening HF events in
the placebo group. We did not find an excess in urinary tract
infections or other adverse effects with the use of empagliflozin.
There were 8 serious adverse events in the empagliflozin group
vs. 11 in the placebo group (P = 0.54). The causes of these
events are listed in online supplementary Table S2. Overall seven
patients in the empagliflozin group and five patients in the placebo
group discontinued study medication due to AE (P = 0.36) (online
supplementary Table S3). There was no difference in the occur-
rence of AESI. Four patients (10%) in the empagliflozin and three
patients (8%) in the placebo group developed a worsening renal
function AESI (P = 0.74), while one patient with type 2 diabetes
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics
Variable Randomized treatment P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Empagliflozin Placebo
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patients (n) 40 39
Age (years) 79 (73–83) 73 (61–83) 0.14
Female sex, n (%) 16 (40) 10 (26) 0.17
Caucasian race (%) 100 95 0.15
Body weight at baseline (kg) 87± 23 83± 20 0.42
SBP (mmHg) 127± 22 121± 25 0.25
DBP (mmHg) 76±15 72± 15 0.27
HR (bpm) 83±19 80± 23 0.50
Respiratory rate (breaths/min) 19± 4 20± 5 0.60
NYHA class III/IV (%) 92 97 0.57
LVEF if known (%) (n = 46) 36±17 37± 14 0.87
De novo acute HF (%) 48 46 0.90
Ischaemic aetiology (%) 28 29 0.89
Medical history (%)
Myocardial infarction 30 38 0.43
Hypertension 68 56 0.31
Atrial fibrillation/flutter 78 64 0.19
Diabetes mellitus type 2 38 28 0.38
Cerebrovascular accident 5 5 0.98
COPD 28 26 0.85
Cancer 38 13 0.012
Medical therapy (%)
ACEi 40 47 0.51
ARB 5 3 0.45
ARNI 5 3 0.52
Beta-blocker 70 66 0.69
MRA 48 45 0.81
Loop diuretic 100 100 NA
Intravenous vasodilator 10 3 0.36
ICD 8 23 0.054
CRT 15 13 0.78
Laboratory at baseline
NT-proBNP (pg/mL) 4406 (2873–6979) 6168 (3180–10 489) 0.14
Serum creatinine (μmol/L) 114± 34 116± 33 0.72
eGFR (mL/min/1.73 m2) 55±18 55± 18 0.97
Sodium (mmol/L) 135± 17 135± 5 0.99
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; COPD, chronic obstructive pulmonary
disease; CRT, cardiac resynchronization therapy; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, heart rate; ICD, implantable
cardioverter defibrillator; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NA, not applicable; NT-proBNP, N-terminal pro brain natriuretic
peptide; NYHA, New York Heart Association; SBP, systolic blood pressure.
in the placebo group experienced diabetic ketoacidosis (online
supplementary Table S4). There was no sign that empagliflozin was
associated with more renal events as the renal/urinary AE rate was
similar, and the occurrence of worsening renal function or acute
kidney injury was also not different between treatment groups.
Online supplementary Table S5 lists all individual AE.
Discussion
In this randomized, double-blind, placebo-controlled, multicen-
tre pilot study on the safety and efficacy of empagliflozin in

















.. reduction in NT-proBNP, diuretic response (weight loss per
40 mg furosemide) and length of hospital stay were similar with
empagliflozin and placebo. Empagliflozin increased cumulative
urinary volume and net fluid balance in a subset of patients.
Importantly, empagliflozin appeared to be safe and well tolerated,
without major effects on heart rate and blood pressure. Finally,
we observed significantly fewer deaths, in-hospital worsening of
HF and/or HF readmissions through day 60.
As far as we know, this is the first randomized, double-blind,
placebo-controlled trial on the effects of a SGLT2 inhibitor in
patients with acute HF. SGLT2 inhibitors were originally designed
as glucose-lowering agents for glycaemic control. In four large
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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A B
C D
Figure 2 Primary endpoints. (A) Change in visual analogue scale (VAS) dyspnoea. (B) Diuretic response. (C) Percentage change in N-terminal
pro brain natriuretic peptide (NT-proBNP). (D) Length of stay. Error bars represent 80% confidence intervals for (B) and (C). AUC, area under
the curve; SD, standard deviation.
randomized controlled trials in patients with diabetes, SGLT2
inhibitors consistently reduced cardiovascular events, and HF
hospitalizations in particular. These data prompted the design of
large phase III clinical trials on the effects of SGLT2 inhibitors in
patients with established chronic HF, irrespective of whether they
had diabetes or not.20,21 Recently, main results of the first trial,
Dapagliflozin and Prevention of Adverse Outcomes in Heart Fail-
ure (DAPA-HF), were presented and published.9 In 4474 patients
with HFrEF with and without diabetes, dapagliflozin reduced the
risk of a composite endpoint of worsening HF (hospitalization or an
urgent visit resulting in intravenous therapy for HF) or cardiovas-
cular death. These effects were accompanied by an improvement
of quality of life. These beneficial effects of dapagliflozin in patients
with HFrEF on quality of life were recently confirmed in a smaller
study.22 Until now, no data on the effects of SGLT2 inhibitors in
patients admitted with acute HF, irrespective of left ventricular

























. In the present study, we could not show any significant dif-
ferences for the primary endpoints between empagliflozin and
placebo. First, despite both a significantly greater urinary output
and a more negative net fluid balance, there was no reduction
in dyspnoea, as recorded by a VAS. Second, we did not observe
an improvement in diuretic response, defined as weight change
per 40 mg of furosemide (or equivalent dose of another loop
diuretic).18 This endpoint was chosen to correct for a decreased
use of loop diuretic when symptoms had recovered more quickly
in the empagliflozin treated patients. However, symptoms in hos-
pital did not recover more quickly and diuretic use during the first
4 days were similar in both groups. Thirdly, although we observed
an expected large drop in NT-proBNP in the first days of hospital
admission in all patients, we did not demonstrate a greater drop
in patients treated with empagliflozin. These findings are similar to
a recent study with dapagliflozin in patients with chronic HFrEF.22
Finally, length of hospital stay was not shortened by empagliflozin,
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Z-score presentation of primary endpoints and combined z-score. CI, confidence interval; NT-proBNP, N-terminal pro brain
natriuretic peptide; SD, standard deviation; VAS, visual analogue scale.
Figure 4 Clinical events. HF, heart failure; WHF, worsening heart failure.
probably since it may be determined by multiple factors other than
those specifically related to improvement in HF, particularly in an
elderly, fragile, high-risk patient cohort such as included in this
study.
We observed a significant reduction of a combined endpoint
of in-hospital worsening HF, death and/or hospital readmission
through day 60. However, these data should be interpreted with
caution for two major reasons. Firstly, this study was not powered
and not designed to show an effect on clinical endpoints, and the















. reduction in the pre-defined secondary endpoint of death and/or
hospital readmission within 30 days. Nevertheless, the reduction
in clinical endpoints is consistent with previous morbidity and
mortality benefits for SGLT2 inhibitors in diabetes and in line with
results of the DAPA-HF trial in patients with chronic HFrEF.9 If
anything, our results suggest this novel HF treatment can safely be
initiated in a high-risk population of acute HF patients and should
pave the way for larger studies.
Although loop diuretics and nitrates (in selected patients) remain
the mainstay of the treatment of acute HF, several drugs have been
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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A B
Figure 5 Urinary output and net fluid balance through day 4. (A) Cumulative urine output. (B) Cumulative net fluid balance. CI, confidence
interval.






. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Overall 55 63
Cardiovascular 9 (23) 17 (44) 0.046
Respiratory 3 (8) 2 (5) 0.67
Gastrointestinal 6 (15) 9 (23) 0.36
Psychiatric 0 (0) 1 (3) 0.31
Renal/urinary 15 (38) 13 (33) 0.70
Reproductive 0 (0) 0 (0) NA
Metabolic 9 (23) 9 (23) 0.95
Musculoskeletal 5 (13) 5 (13) 0.97
Thromboembolic 1 (3) 0 (0) NA
Infectious 1 (3) 0 (0) 0.32
Other 6 (15) 7 (18) 0.72
NA, not applicable.
First events in a category in an individual patient are shown as n (%).
investigated but failed to improve clinical outcomes in patients
with acute HF. Most of these investigational drugs had significant
effects on blood pressure and/or renal function.23–25 However,
in our small pilot study, we did not find any clinically relevant
effect on blood pressure, heart rate, or renal function. In addition,
empagliflozin drug was safe and well tolerated with less AE than
in placebo treated patients. Specifically, empagliflozin therapy was
not associated with more frequent worsening of renal function or
renal AE.
Finally, we found a remarkable effect on urinary output and
net fluid balance. These findings strongly support an incremental
diuretic effect with empagliflozin treatment, which has not been
previously shown in patients with HF. The disconnect between this
increase in diuresis, without an effect on symptoms or markers




















































. between these variables in clinical practice. Whether the beneficial
effects of SGLT2 inhibitors on clinical outcomes in patients with
HFrEF are related to their diuretic effect or whether they are
mediated via other pathways where SGLT2 inhibitors exert their
actions remains to be established.
Limitations
This study has several limitations. First and foremost, this study
is limited by the number of patients and should be considered as
a pilot study. The results of this study should therefore be inter-
preted with caution. Secondly, we screened many more patients
than were included in the study due to different reasons. Although
for this reason the generalizability of the finding to the average
acute HF patient can be questioned, the characteristics of our
patients included suggest it represents the phenotype of acute HF
patients currently admitted. Thirdly, the number of missing urinary
collections and fluid intake limits the interpretability of the data
on urinary output and net fluid loss, although an effect was already
observed after 24 h. Finally, there was no standardized protocol for
in-hospital treatment of acute HF and no protocol for diuretic ther-
apy, which means individual differences in the treatment of these
patients may have impacted the results.
Conclusion
In this randomized, double-blind, placebo-controlled pilot study in
patients with acute (decompensated) HF, empagliflozin was safe and
well tolerated, but did not improve dyspnoea, NT-proBNP, diuretic
response and length of hospital stay. However, empagliflozin was
associated with greater urinary output and a reduction in a com-
bined endpoint of worsening HF, rehospitalization for HF or death
at 60 days. Larger randomized clinical trials with SGLT2 inhibitors
are greatly needed to further study the possible beneficial role of
SGLT2 inhibitors in patients with acute HF.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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